FDA approves Xocova for COVID-19 prevention after exposure

The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to someone with the disease, according to the drug’s manufacturer, Shionogi.Xocova (ensitrelvir) was approved as COVID-19 post-exposure prophylaxis for patients aged 12 years or older, the drug maker announced.

lunedì 1 giugno 2026 New tab

June 01, 2026

2 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

FDA approves Xocova for COVID-19 prevention after exposure

FDA approves Xocova for COVID-19 prevention after exposure

Other newsrooms on this story

Related reading

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure…

Shionogi wins US approval for first pill to prevent Covid following exposure

At last, a pill that can prevent COVID after exposure to infected people

No Pill Currently Prevents Covid-19. This One Just Might

COVID, una pillola riduce il rischio dopo il contagio in casa

Korean scientists say they developed oral drug against COVID-19 - UPI.com

Other newsrooms on this story

Related reading

Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure…

Shionogi wins US approval for first pill to prevent Covid following exposure

At last, a pill that can prevent COVID after exposure to infected people

No Pill Currently Prevents Covid-19. This One Just Might

COVID, una pillola riduce il rischio dopo il contagio in casa

Korean scientists say they developed oral drug against COVID-19 - UPI.com